Optimizing drug delivery systems using systematic "design of experiments." Part II: Retrospect and prospects

Critical Reviews in Therapeutic Drug Carrier Systems

Volumn 22, Issue 3, 2005, Pages 215-293

  Singh, Bhupinder ^a   Dahiya, Manju ^a   Saharan, Vandana ^a   Ahuja, Naveen ^a  

^a PANJAB UNIVERSITY   (India)

Author keywords

Artificial neural networks; Box Behnken design; Composite design; Drug formulation; Experimental design; Factorial design; Mixture design; Optimization; Product development; Response surface methodology

Indexed keywords

ACETYLSALICYLIC ACID; ALPRAZOLAM; BUMETANIDE; CALCIUM PHOSPHATE; CAPTOPRIL; CHLORPHENIRAMINE MALEATE; DICLOFENAC; DIDANOSINE; DILTIAZEM; FLUORIDE; IBUPROFEN; KETOPROFEN; KETOROLAC TROMETAMOL; LOBENZARIT; METFORMIN; METOPROLOL TARTRATE; MICROSPHERE; MISOPROSTOL; NAFTIDROFURYL; NANOPARTICLE; NAPROXEN; NIFEDIPINE; PARACETAMOL; PHENYLPROPANOLAMINE; PROPRANOLOL; ROPIVACAINE; SULFATHIAZOLE; THEOPHYLLINE; TRAPIDIL; UNINDEXED DRUG; VERAPAMIL; DRUG CARRIER; POLYMER;

ADHESION; COLON; CONTROLLED RELEASE FORMULATION; DRUG BIOAVAILABILITY; DRUG COATING; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM; DRUG FORMULATION; DRUG GRANULATION; DRUG SCREENING; EXPERIMENTAL DESIGN; GENE DELIVERY SYSTEM; HYDRODYNAMICS; METHODOLOGY; MICROCAPSULE; MICROENCAPSULATION; OSMOSIS; PELLET EXTRUSION; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; REVIEW; SPHERONIZATION; TABLET MANUFACTURE; TRANSDERMAL PATCH; BIOAVAILABILITY; CHEMISTRY; HUMAN;

BIOLOGICAL AVAILABILITY; CHEMISTRY, PHARMACEUTICAL; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; HUMANS; POLYMERS; RESEARCH DESIGN;

EID: 23844484653     PISSN: 07434863     EISSN: None     Source Type: Journal    
DOI: 10.1615/CritRevTherDrugCarrierSyst.v22.i3.10     Document Type: Review

References (484)

1. Fisher RA. The Design of Experiments. 1 ed. Edinburgh: Oliver and Boyd, 1935.
2. Plackett RL, Burman JP. The design of optimum multifactorial experiments. Biometrika 1946; 33:305-325.
3. Box GEP, Wilson KB. On the experimental attainment of optimum conditions. J Royal Stat Soc Ser B 1951; 13:1-45.
4. Scheffé H. Experiments with mixtures. J Royal Stat Soc Ser B 1958; 20:344-360.
5. Marlowe E, Shangraw RF. Dissolution of sodium salicylate from tablet matrices prepared by wet granulation and direct compression. J Pharm Sci 1967; 56:498-504.
6. Lindberg NO, Holmquist B. Optimizing the friability of a tablet formulation. Drug Dev Ind Pharm 1987; 13:1063-1067.
7. Renoux R, Demazieres JA, Cardot JM, Aiache JM. Experimentally designed optimization of direct compression tablets. Drug Dev Ind Pharm 1996; 22:103-109.
8. Rege BD, Gawel J, Kou JH. Identification of critical process variables for coating actives onto tablets via statistically designed experiments. Int J Pharm 2002; 237:87-94.
9. El-Banna HM, Sautin SN. Interaction of factors in the factorial design of experiments for preparing effervescent tablets. Sci Pharm 1980; 48:369-377.
10. Gohel MC, Gopi MR, Shah A, Momin SR, Patel KV, Gandhi KB. Application of simplex analysis for development of dispersible tablets of cyproheptadine hydrochloride. Indian J Pharm Sci 1994; 56:24-27.
11. Eddington ND, Ashraf M, Augsburger LL, Leslie JL, Fossler MJ, Lesko LJ, Shah VP, Rekhi GS. Identification of formulation and manufacturing variables that influence in vitro dissolution and in vivo bioavailability of propranolol hydrochloride tablets. Pharm Dev Technol 1998; 3:535-547.
12. Timmins P, Delargy AM, Howard JR. Optimization and characterization of a pH-independent extended-release hydrophilic matrix tablet. Pharm Dev Technol 1997; 2:25-31.
13. McGurk JG, Lendrem DW, Potter CJ. Use of statistical experimental design in laboratory scale formulation optimization and progression to plant scale. Drug Dev Ind Pharm 1991; 17:2341-2358.
14. Newton JM, Razzo FN. The influence of additives on the presentation of a drug in hard gelatin capsules. J Pharm Pharmacol 1977; 29:294-297.
15. Newton JM, Razzo FN. The in vitro bioavailability of various drugs formulated as hard gelatin capsules. J Pharm Pharmacol 1977; 29:205-208.
16. Abuzarur-Aloul R, Gjellan K, Sjolund M, Graffner C. Critical dissolution tests of oral systems based on statistically designed experiments. III. In vitroin vivo correlation for multiple-unit capsules of paracetamol based on PLS modelling. Drug Dev Ind Pharm 1998; 24:371-383.
17. Dashevsky A, Bussemer T, Mohamad A, Bodmeier R. Process and formulation variables affecting the performance of a rupturable capsule-based drug delivery system with pulsatile drug release. Drug Dev Ind Pharm 2004; 30:171-179.
18. Iskandarani B, Clair J, Shiromani P, Dempski R. Simultaneous optimization of capsule and tablet formulation using response surface methodology. Drug Dev Ind Pharm 1993; 19:2089-2101.
19. Hogan J, Shue P, Podczeck F, Newton J. Investigations into the relationship between drug properties, filling, and the release of drugs from hard gelatin capsules using multivariate statistical analysis. Pharm Res 1996; 13:944-949.
20. deSaavedra MS, Cuadra IIS. Application of a mixed optimization strategy in the design of a pharmaceutical solid formulation at laboratory scale. Drug Dev Ind Pharm 2001; 27:675-685.
21. Nguyen NA, Wells ML, Cooper DC. Identification of factors affecting preservative efficacy and chemical stability of lamivudine oral solution through statistical experimental design. Drug Dev Ind Pharm 1995; 21:1671-1682.
22. Senderak E, Bonsignore H, Mungan D. Response surface method as an approach to optimization of an oral solution. Drug Dev Ind Pharm 1993; 19:405-424.
23. Bjerregaard S, Soderberg I, Vermehren C, Frokjaer S. Formulation and evaluation of release and swelling mechanism of a water-in-oil emulsion using factorial design. Int J Pharm 1999; 193:1-11.
24. Nielloud F, Marti-Mestres G, Fortune R, Mestres JP, Maillols H. Formulation of insoluble drugs. Study of pharmaceutical suspensions by response surface methodology. Analusis 1998; 26:277-281.
25. Brisaert M, Gabriels M, Vercammen J. Investigation on the chemical stability of an erythromycin-tretinoin lotion by the use of an optimization system. Int J Pharm 2000; 197:153-160.
26. Ozil P, Rochat MH. Experimental design, an efficient tool for studying the stability of parenteral nutrition. Int J Pharm 1988; 42:11-14.
27. El-Ghawad NAA. Optimization of the microemulsion formation using central composite design. Bull Fac Pharm 1997; 35:131-136.
28. Nielloud F, Marti-Mestres G, Laget JP, Fernandes C, Maillos H. Emulsion formulations study of the influence of parameters with experimental design. Drug Dev Ind Pharm 1996; 22:159-166.
29. Pattarino F, Marengo E, Gasco MR, Carpignano R. Experimental design and partial least squares in the study of complex mixtures: microemulsions as drug carriers. Int J Pharm 1993; 91:157-165.
30. Patel JP, Marsh K, Carr L, Nequist G. Factorial designs in ophthalmic formulation development of enalkiren. Int J Pharm 1990; 65:195-200.
31. 3 factorial design and the desirability function. Ars Pharmaceutica 2004; 45:253-279.
32. Awwadi MR, Ghassemi AH, Akbarzadeh A, Nahid E, Rafiee-Tehrani M. Preparation and evaluation of theophylline chitosan beads based on factorial design studies for colon drug delivery. In: Proceedings of 30th Annual Meeting of Controlled Release Society; Scotland, UK, 2003; Abstract 355.
33. Hu H, Song H, Chen D, Ge Y, Ma Y. Preparation and optimization of formulation of enteric coated omeprazole pellets. Zhongguo Yaoxue Zazhi 2003; 38:780-781.
34. Graffner C, Särkelä M, Gjellan K, Nork G. Use of statistical experimental design in the further development of a discriminating in vitro release test for ethyl cellulose ER-coated spheres of remoxipride. Eur J Pharm Sci 1996; 4:73-83.
35. Khan MA, Bolton S, Kislalioglu MS. Optimization of process variables for the preparation of ibuprofen coprecipitates with Eudragit S100. Int J Pharm 1994; 102: 185-192.
36. Singh B, Agarwal R. Design development and optimization of controlled release microcapsules of diltiazem hydrochloride. Indian J Pharm Sci 2002; 64:378-385.
37. Devay A, Racz I. Examination of parameters determining particle size of sulfamethoxazole microcapsules prepared by a new melt dispersion method. Pharm Ind 1984; 46: 101-103.
38. Devay A, Fekete P, Racz I. Application of factorial design in the examination of tofizopam microcapsules. J Microencapsul 1984; 1:299-305.
39. Mani N, Jun HW. Microencapsulation of a hydrophilic drug into a hydrophobic matrix using a salting-out procedure. I: Development and optimization of the process using factorial design. J Microencapsul 2004; 21:125-135.
40. Parikh RH, Parikh JR, Dubey RR, Soni HN, Kapadia KN. Pory(D,L-lactide-co- glycolide) microspheres containing 5-fluorouracil: optimization of process parameters. AAPS PharmSciTech 2003; 4: Article 13.
41. Liu Z, Zhang L, Lu W, Pan J. Optimized formulation of amoxicillin bioadhesive microspheres using central composite design. Zhongguo Yiyao Gongye Zazhi 2003; 34:280-282.
42. Dillen K, Vandervoort J, Van den Mooter G, Verheyden L, Ludwig A. Factorial design, physicochemical characterisation and activity of ciprofloxacin-PLGA nanoparticles. Int J Pharm 2004; 275:171-187.
43. Yang SC, Zhu JB. Preparation and characterization of camptothecin solid lipid nanoparticles. Drug Dev Ind Pharm 2002; 28:265-274.
44. Seth AK, Misra A, Umrigar D. Topical liposomal gel of idoxuridine for the treatment of Herpes simplex: pharmaceutical and clinical implications. Pharm Dev Technol 2004; 9:277-289.
45. Bhalerao SS, Raje Harshal A. Preparation, optimization, characterization, and stability studies of salicylic acid liposomes. Drug Dev Ind Pharm 2003; 29:451-467.
46. Zhang ZR, Wang JX, Lu J. Optimization of the preparation of 3′,5′-dioctanoyl-5-fluoro-2′-deoxyuridine pharmacosomes using central composite design. Yao Xue Xue Bao 2001; 36:456-461.
47. Devay A, Schaffer M, Racz I, Kovacs P. Application of factorial experiment project for optimization of manufacturing technology of theophylline suppositories. Acta Pharm Hung 1988; 58:201-207.
48. Takayama K, Okabe H, Obata Y, Nagai T. Formulation design of indomethacin gel ointment containing d limonene using computer optimization methodology. Int J Pharm 1990; 61:225-234.
49. Keyhani-Morrison E, Nadkarni S, Sakr A. Optimization of gel formulations of a novel retinoid based on experimental design. Pharm Ind 1995; 57:333-337.
50. Hwang GC, Lin AY, Chen W, Sharpe RJ. Development and optimization of a methotrexate topical formulation. Drug Dev Ind Pharm 1995; 21:1941-1952.
51. Sheu M-T, Chen L-C, Ho H-O. Simultaneous optimization of percutaneous delivery and adhesion for ketoprofen poultice. Int J Pharm 2002; 233:257-262.
52. Agarwal V, Singh SK, Reddy IK, Durrani MJ, Khan MA. Cataplasm-based controlled drug delivery: development and optimization of a novel formulation. Drug Dev Ind Pharm 1999; 25:659-665.
53. Mendes PJ, Raposo A, Sousa JMM, Pinto JF. Sizing of powders in inhalers with an aerosizer according to a mixed experimental factorial design. J Aerosol Sci 2004; 35: 509-527.
54. Ståhl K, Claessonb M, Lilliehornc P, Lindénd H, Bäckströmd K. The effect of process variables on the degradation and physical properties of spray dried insulin intended for inhalation. Int J Pharm 2002; 233:227-237.
55. Fedina LT, Zelko R, Fedina LI, Szabados Z, Szanto M. Comparative evaluation of surfactant and hydrophobizing agent concentration in relation to the optimal particle size of metered-dose inhalers. Drug Dev Ind Pharm 1998; 24: 853-856.
56. Juslin L, Antikainen O, Merkku P, Yliruusi J. Droplet size measurement. Part 1. Effect of three independent variables on droplet size distribution and spray angle from a pneumatic nozzle. Int J Pharm 1995; 123:247-256.
57. Nagarsenker MS, Hegde DD. Optimization of the mechanical properties and water-vapor transmission properties of free films of hydroxypropylmethylcellulose. Drug Dev Ind Pharm 1998; 25:95-98.
58. Akitoshi Y, Takayama K, Machida Y, Nagai T. Computer optimization of the formulation of acrylic plaster. Chem Pharm Bull 1985; 33:4536-4543.
59. Gao JZH, Jain A, Motheram R, Gray DB, Hussain MA. Fluid bed granulation of a poorly water soluble, low density, micronized drug: comparison with high shear granulation. Int J Pharm 2002; 237:1-14.
60. Gohel MC, Jogani PD. Exploration of melt granulation technique for the development of coprocessed directly compressible adjuvant containing lactose and microcrystalline cellulose. Pharm DevTechnol 2003; 8:175-185.
61. Ameye D, Keleb E, Vervaet C, Remon JP, Adams E, Massart DL. Scaling-up of a lactose wet granulation process in Mi-Pro high shear mixers. Eur J Pharm Sci 2002; 17:247-251.
62. Rambali B, Baert L, Massart DL. Using experimental design to optimize the process parameters in fluidized bed granulation on a semi-full scale. Int J Pharm 2001; 220: 149-160.
63. Badawy SIF, Menning MM, Gorko MA, Gilbert DL. Effect of process parameters on compressibility of granulation manufactured in a high-shear mixer. Int J Pharm 2000; 198:51-61.
64. Tanfara H, Tavanayanfar F, Meisner D, Winters C, Brousseau Y, Emond G, Mountassir M. Optimization of a high shear wet granulation process using Quantisweb and JMPTM. In: Proceedings of Annual Meeting of American Association of Pharmaceutical Scientists (AAPS); Maryland, USA, 2004; Abstract 001609.
65. Wehrlé P, Nobelis P, Cuine A, Stamm A. Scaling up of wet granulation: statistical methodology. Drug Dev Ind Pharm 1993; 19:1983-1997.
66. Miyamoto Y, Ryu A, Sugawra S, Miyajima M, Matsui M, Takayama K, Nagai T. Optimization of granulation process for designing tablets. Chem Pharm Bull 1998; 46:1432-1437.
67. Gabrielsson J, Lindberg NO, Palsson M, Nicklasson F, Sjostrom M, Lundstedt T. Multivariate methods in the development of a new tablet formulation. Drug Dev Ind Pharm 2003; 29:1053-1075.
68. Sabir A, Evans B, Jain S. Formulation and process optimization to eliminate picking from market image tablets. Int J Pharm 2001; 215:123-135.
69. Murray M, Laohavichien A, Habib W, Sakr A. Effect of process variables on roller compacted ibuprofen tablets. Pharm Ind 1998; 60:257-262.
70. Westerhuis JA, Coenegracht PMJ, Lerk CF. Multivariate modelling of the tablet manufacturing process with wet granulation for tablet optimization and in process control. Int J Pharm 1997; 156:109-117.
71. Ruff M, Cobb J. Using Taguchi experimental design (DOE) to meet the 2003 PQRI/FDA draft guidance on stratified sampling and blend uniformity. In: Proceedings of Annual Meeting of American Association of Pharmaceutical Scientists (AAPS); Maryland, USA, 2004; Abstract 000432.
72. Rezaei H, McLaughlin M, Hoover J, Cheruiyot R, Creekmore R. The effect of roller compaction variables on an experimental tablet formulation using a full factorial experimental design. In: Proceedings of Annual Meeting of American Association of Pharmaceutical Scientists (AAPS); Maryland, USA, 2004; Abstract 002229.
73. Heinamaki J, Ruotsalainen M, Lehtola VM, Antikainen O, Yliruusi J. Optimization of aqueous-based film coating of tablets performed by a side-vented pan-coating system. Pharm Dev Technol 1997; 2:357-364.
74. Parikh NH, Porter SC, Rohera BD. Aqueous ES dispersion of EC 1. Evaluation of coating process variables. Pharm Res 1993; 10:525-535.
75. Cole GC, May G, Neale PJ, Olver MC, Ridgway K. Design and performance of an instrumentation system for aqueous film coating in an industrial tablet coating machine. Drug Dev Ind Pharm 1983; 9:909-944.
76. Devay A, Racz I. Factorial pilot project for the optimization of technological parameters of film coating in the manufacturing process. 1. labratory manufacture of enteric-coated tablets and their analysis. Acta Pharm Hung 1986; 56:227-231.
77. Devay A, Kovacs B, Uderszky J, Domotor Z. Multifactorial design optimization of film coating technique. Pharm Ind 1982; 44:830-838.
78. Li LC, Peck GE. Water based silicone elastomer controlled release tablet film coating. V. A statistical approach. Drug Dev Ind Pharm 1991; 17:27-37.
79. Kennedy JP, Niebergall PJ. Development and optimization of a solid dispersion hot-melt fluid bed coating method. Pharm Dev Technol 1996; 1:51-62.
80. Plumb AP, Rowe RC, York P, Doherty C. The effect of experimental design on the modeling of a tablet coating formulation using artificial neural networks. Eur J Pharm Sci 2002; 16:281-288.
81. Krogars K, Antikainen O, Heinamaki J, Laitinen N, Yliruusi J. Tablet film-coating with amylose-rich maize starch. Eur J Pharm Sci 2002; 17:23-30.
82. Chariot M, Frances J, Lewis GA, Matheiu D, Phan-Tan-Luu R. A factorial approach to process variables of extrusion spheronization of wet powder masses. Drug Dev Ind Pharm 1987; 13:1639-1649.
83. Ku CC, Joshi YM, Bergum JS, Jain NB. Bead manufacture by extrusion/spheronization: statistical design for process optimization. Drug Dev Ind Pharm 1993; 13:1505-1519.
84. Korakianiti ES, Rekkas DM, Dallas PP, Choulis NH. Optimization of the pelletization process in a fluid-bed rotor granulator using experimental design. AAPS PharmSciTech 2000; 1: Article 35.
85. Heng PWS, Chan LW, Zhu L. Effects of process variables and their interactions on melt pelletization in a high shear mixer. STP Pharm Sci 2000; 10:165-172.
86. Jones DS, Pearce KJ. An investigation of the effects of some process variables on the microencapsulation of propranolol hydrochloride by the solvent evaporation method. Int J Pharm 1995; 118:199-205.
87. Wehrlé P, Stamm. A. Statistical tools for process control and quality improvement in the pharmaceutical industry. Drug Dev Ind Pharm 1994; 20:141-164.
88. Achanta AS, Kowalski JG, Rhodes CT. Artificial neural networks: implications for pharmaceutical sciences. Drug Dev Ind Pharm 1995; 21:119-155.
89. Lewis GA, Mathieu D, Phan-Tan-Luu R. Pharmaceutical Experimental Design. New York: Marcel Dekker, 1999.
90. Alkhatib HS, Sakr A. Optimization of methacrylic acid ester copolymers blends as controlled release coatings using response surface methodology. Pharm Dev Technol 2003; 8:87-96.
91. Belloto Jr RJ, Dean AM, Moustafa MA, Molokhia AM, Gouda MW, Sokoloski TD. Statistical techniques applied to solubility predictions and pharmaceutical formulations: An approach to problem solving using mixture response surface methodology. Int J Pharm 1985; 23:195-207.
92. Dietrich R, Brausse R. Validation of the pellet coating process used for a new sustained-release theophylline formulation. Arzneimittelforschung 1988; 38:1210-1219.
93. Bouckaert S, Massart DL, Massart B, Remon JP. Optimization of a granulation procedure for a hydrophilic matrix tablet using experimental design. Drug Dev Ind Pharm 1996; 22:321-327.
94. Law MF, Deasy PB. Use of canonical and other analyses for the optimization of an extrusion-spheronization process for indomethacin. Int J Pharm 1997; 146:1-9.
95. Abu-Izza K, Garcia-Contreras L, Lu DR. Preparation and evaluation of ziduvudine loaded sustained release microspheres. 2. Optimization of multiple response variables. J Pharm Sci 1996; 85:572-576.
96. Marengo E, Cavalli R, Rovero G, Gasco MR. Scale-up and optimization of an evaporative drying process applied to aqueous dispersions of solid lipid nanoparticles. Pharm Dev Technol 2003; 8:299-309.
97. Bodea A, Leucuta SE. Optimization of propranolol hydrochloride sustained release pellets using Box-Behnken design and desirability function. Drug Dev Ind Pharm 1998; 24:145-155.
98. Sanchez-Lafuente C, Furlanetto S, Fernandez-Arevalo M, Alvarez-Fuentes J, Rabasco AM, Faucci MT, Pinzauti S, Mura P. Didanosine extended-release matrix tablets: optimization of formulation variables using statistical experimental design. Int J Pharm 2002; 237:107-118.
99. Ogawa N, Morishita M, Takayama K, Nagai T. Quantitative evaluation of in vitro release medium to predict transfer of flunisolide into nasal mucosa of rabbits from ointments. S T P Pharm Sci 2003; 13:259-263.
100. Takayama K, Obata Y, Morishita M, Nagai T. Multivariate spline interpolation as a novel method to optimize pharmaceutical formulations. Pharmazie 2004; 59: 392-395.
101. Takayama K, Takahara J, Fujikawa M, Ichikawa H, Nagai T. Formula optimization based on artificial neural networks in transdermal drug delivery. J Control Release 1999; 62:161-170.
102. Wu P-C, Obata Y, Fujikawa M, Li CJ, Higashiyama K, Takayama K. Simultaneous optimization based on artificial neural networks in ketoprofen hydrogel formula containing o-ethyl-3-butylcyclohexanol as percutaneous absorption enhancer. J Pharm Sci 2001; 90:1004-1014.
103. Löbenberg R, Amidon GL, Vieira M. Solubility as a limiting factor to drug absorption. In: Dressman JB, Lennernäs H, editors. Oral Drug Absorption: Prediction and Assessment. New York: Marcel Dekker, 2000.
104. Kumar MNVR. Nano and microparticles as controlled drug delivery devices. J Pharm Pharmaceut Sci 2000; 3:234-258.
105. Robinson JR, Lee VHL. Controlled Drug Delivery: Fundamentals and Applications. New York: Marcel Dekker, 1987.
106. Harris MR, Schwartz JB, McGinity JW. Optimization of a slow release tablet formulation containing sodium sulphathiazole and a montmorrilonite clay. Drug Dev Ind Pharm 1985; 11:1089-1110.
107. Franz RM, Sytsma JA, Smith BP, Lucisano LJ. In vitro evaluation of a mixed polymeric sustained release matrix using RSM. J Control Release 1987; 5:159-172.
108. Joly F, Brossard C. Development of a hydrophilic matrix for theophylline. Part 1. Physical and mechanical properties of materials and optimization of formulation. STP Pharm Pratiques 1987; 3:556-568.
109. Bodea A, Leucuta SE. Optimization of hydrophilic matrix tablets using a D-optimal design. Int J Pharm 1997; 153:247-255.
110. Gohel MC, Patel KV. Formulation optimization of diltiazem hydrochloride matrix tablets containing modified ispaghula husk using factorial design. Drug Dev Ind Pharm 1997; 23:1055-1061.
111. Waaler P, Graffner C, Muller B. Optimization of a matrix tablet formulation using a mixture design. Acta Pharm Nord 1992; 4:9-16.
112. Waaler PJ, Arnesen K, Graffner C, Muller BW. Optimization of the amount of xanthan gum and guar gum in a matrix tablet formulation using a central composite design. Acta Pharm Nord 1992; 4:291-296.
113. Li LC, Tu YH. In vitro drug release from matrix tablets containing a silicone elastomer latex. Drug Dev Ind Pharm 1991; 17:2197-2214.
114. Singh B, Bakshi M, Agarwal R, Madella RB. Optimization of lipid matrix formulations of captopril through response surface methodology. In: Proceedings of 50th Indian Pharmacutical Congress; Mumbai, India, 1998; Abstract IAP37.
115. Dincer S, Ozdurmus S. Mathematical model for enteric film coating of tablets. J Pharm Sci 1977; 66:1070-1073.
116. Lu E, Jiang Z, Jiang X, Zhang Q. Preparation of controlled release coated tablets of naproxen sodium. Zhongguo Yaoxue Zazhi 2002; 37:841-844.
117. Colombo P. Swelling-controlled release in hydrogel matrices for oral route. Adv Drug Deliv Rev 1993; 11:37-57.
118. Gohel MC, Panchal MK. Formulation optimization of diltiazem-HCl matrix tablets containing modified guar gum using a central composite design. Pharm Pharmacol Commun 1999; 5:331-338.
119. Gohel MC, Amin AF, Chhabaria MT, Panchal MK, Lalwani AN. Modulation of drug release rate of diltiazem-HCl from hydrogel matrices of succinic acid-treated ispaghula husk. Pharm Dev Technol 2000; 5:375-381.
120. Gohel MC, Patel KV, Panchal MK, Doctor BB, Shah PD. Application of simplex lattice design to the preparation of sustained-release diltiazem hydrochloride tablets using modified guar gum. Indian J Pharm Sci 1999; 61:162-167.
121. Danckwerts MP, Van der Watt JG, Moodley I. The effect of processing variables on the release of ibuprofen and caffeine from controlled-release nonswellable core-in-cup compressed tablets. Drug Dev Ind Pharm 1996; 22:681-687.
122. Bonferoni MC, Rossi S, Ferrari F, Stavik E, Pena-Romero A, Caramella C. Factorial analysis of the influence of dissolution medium on drug release from carrageenan-diltiazem complexes. AAPS PharmSciTech 2000; 1: Article 15.
123. Lewis GA, Chariot M. Non classical experimental designs in pharmaceutical formulations. Drug Dev Ind Pharm 1991; 17:1551-1570.
124. Tillotson J, Sakr A. Application of multiple-response optimization to fluoride release from an extended-release matrix tablet. Pharm Ind 2004; 66:601-606.
125. Huang Y, Khanvilkar KH, Moore AD, Hilliard-Lott M. Effects of manufacturing process variables on in vitro dissolution characteristics of extended-release tablets formulated with hydroxypropyl methylcellulose. Drug Dev Ind Pharm 2003; 29:79-88.
126. Gohel MC, Patel MM, Amin AF. Development of modified release diltiazem HCl tablets using composite index to identify optimal formulation. Drug Dev Ind Pharm 2003; 29:565-574.
127. Li J, Dong E, Li H, Pan W. Studies on the factors influencing metformin hydrochloride release from matrix tablets and the optimization of formulation. Shenyang Yaoke Daxue Xuebao 2003; 20:88-92.
128. Singh B, Buhary MS, Ahuja N, Chaturvedi SC. Formulation optimization and characterization of hydrophilic matrices of verapamil hydrochloride using central composite design (CCD). In: Proceedings of 54th Indian Pharmacutical Congress; Pune, India, 2002; Abstract A54.
129. 3 full factorial design. Drug Dev Ind Pharm 2002; 28:601-608.
130. Miñarro M, García-Montoya E, Suñé-Negre JM, Ticó JR. Study of formulation parameters by factorial design in metoprolol tartrate matrix systems. Drug Dev Ind Pharm 2001; 27:965-973.
131. Vatsaraj N, Zia H, Needham T. Formulation and optimization of a sustained-release tablet of ketorolac tromethamine. Drug Deliv 2002; 9:153-159.
132. Ahrabi SF, Madsen G, Dyrstad K, Sande SA, Graffner C. Development of pectin matrix tablets for colonic delivery of model drug ropivacaine. Eur J Pharm Sci 2000; 10:43-52.
133. Rekhi GS, Nellore RV, Hussain AS, Tillman LG, Malinsowski HJ, Augsburger LL. Identification of critical formulation and processing variables for metoprolol tartarate extended release (ER) matrix tablets. J Control Release 1999; 59:327-342.
134. Gohel MC, Jani GK, Patel NK, Gondaliya DP. Optimization of hydrophilic matrix tablet formulation of diclofenac sodium using a mixture design. Pharm Pharmacol Commun 1998; 4:433-438.
135. Bonferoni MC, Rossi S, Ferrari F, Bertoni M, Bolhuis GK, Caramella C. On the employment of 1/ carrageenan in a matrix system. Part 3. Optimization of a 1/ carrageenan-HPMC hydrophilic matrix. J Control Release 1998; 51:231-239.
136. Geoffroy J-M, Fredrickson JK, Shelton JT. A mixture experiment approach for controlling the dissolution rate of sustained release tablet. Drug Dev Ind Pharm 1998; 24:799-806.
137. th Indian Pharmaceutical Congress; Thiruvanthapuram, India, 1997; Abstract A39.
138. Hariharan M, Gupta V, Price JC. Optimization of sustained-release tablet formulations: a four component mixture experiment. Pharm Dev Technol 1997; 2:365-371.
139. Takahara J, Takayama K, Nagai T. Multi-objective simultaneous optimization technique based on an artificial neural network in sustained release formulations. J Control Release 1997; 49:11-20.
140. Dangprasirt P, Ritthidej GC. Development of diclofenac sodium controlled release solid dispersion tablet using optimization strategy. Drug Dev Ind Pharm 1997; 23: 843-848.
141. Matsumura M, Nakagami H, Yamao T, Takayama K, Nagai T. Computer optimization for the formulation of controlled release theophylline tablet made of micronized low substituted hydroxypropylcellulose and methylcellulose. Chem Pharm Bull 1994; 42: 1902-1908.
142. Kristl A, Vojnovic D, Karba R, Mrhar A, Rubessa F, Zupani B. Mixture design of theophylline retard formulation. Int J Pharm 1993; 100:33-40.
143. Shah S, Morris J, Sulaiman A, Farhadieh B, Truelove J. Development of misopristol 3 hour controlled release formulations using response surface methodology. Drug Dev Ind Pharm 1992; 18:1079-1098.
144. Hussain AS, Yu XQ, Johnson RD. Application of neural computing in pharmaceutical product development. Pharm Res 1991; 8:1248-1252.
145. Johnson AD, Anderson VL, Peck GE. Statistical approach for the development of an oral controlled-release matrix tablet. Pharm Res 1990; 7:1092-1097.
146. Pena-Romero A, Poncet M, Jinot J, Chulia D. Statistical optimization of a sustained release form of sodium diclofenac on inert matrices. Part 2. Statistical optimization. Pharm Acta Helv 1988; 63:333-342.
147. Pena-Romero A, Poncet M, Jinot J, Chulia D. Statistical optimization of a controlled release formulation of diclofenac sodium from inert matrices. Part 1. Aptitude for compression and preliminary discussion. Pharm Acta Helv 1988; 63:309-314.
148. Zaghloul AA, Faltinek J, Vaithiyalingam SR, Reddy IK, Khan MA. Naproxen-Eudragit microspheres: screening of process and formulation variables for the preparation of extended release tablets. Pharmazie 2001; 56:321-324.
149. Zaghloul AA, Vaithiyalingam SR, Faltinek J, Reddy IK, Khan MA. Response surface methodology to obtain naproxen controlled release tablets from its microspheres with Eudragit L100-55. J Microencapsul 2001; 18:651-662.
150. Sheng H-L, Wang P, Tu J-S, Yuan L, Pin Q-N. Application of artificial neural networks for formulation designing of matrix tablets. Zhongguo Yiyao Gongye Zazhi 1998; 29: 352-354.
151. Abdel-Rahman AA, Aboutaleb AE, Stamm A, Abdel-Rahman SI, Samy EM. Optimization of Eudragit or cellulosic polymers ibuprofen sustained release systems using principal component analysis. Bull Pharm Sci 1992; 15:63-82.
152. Khan MA, Karnachi AA, Singh SK, Sastry SV, Kislalioglu SM, Bolton S. Controlled release coprecipitates: formulation considerations. J Control Release 1995; 37: 131-141.
153. Parojcic J, Crossed D signuric Z, Jovanovic M, Ibric S. An investigation into the factors influencing drug release from hydrophilic matrix tablets based on novel carbomer polymers. Drug Deliv 2004; 11:59-65.
154. Sakr A, Tillotson J. Effect of extended-release polymer concentration and pH and solubility modifiers on the release of a weakly acid drug from an extended-release, matrix tablet. In: Proceedings of Annual Meeting of American Association of Pharmaceutical Scientists (AAPS); Maryland, USA, 2004; Abstract 000526.
155. Ibric S, Jovanovic M, Crossed D signuric Z, Parojcic J, Petrovic S, Solomun L, Stupar B. Artificial neural networks in the modeling and optimization of aspirin extended release tablets with Eudragit L 100 as matrix substance. AAPS PharmSciTech 2003; 4: Article 9.
156. th Annual Meeting of Controlled Release Society; Scotland, UK, 2003; Abstract 433.
157. Ibric S, Jovanovic M, Crossed D signuric Z, Parojcic J, Solomun L. The application of generalized regression neural network in the modeling and optimization of aspirin extended release tablets with Eudragit® RS PO as matrix substance. J Control Release 2002; 82: 213-222.
158. Khattab IS, Abdel-rahman S, Khidr S, Abdel-Hakiem O. Development and optimization of sustained release captopril tablets and capsules. Egyptian J Biotech 2001; 10: 432-445.
159. Boza A, De la Cruz Y, Jordan G, Jauregui-Haza U, Aleman A, Caraballo I. Statistical optimization of a sustained-release matrix tablet of lobenzarit disodium. Drug Dev Ind Pharm 2000; 26:1303-1307.
160. Plaizier-Vercammen J, Dauwe D, Brioen P. Possibility of the use of Eudragit RS as a sustained-release matrix agent for the incorporation of water-soluble active compounds at high percentages. S T P Pharm Sci 1997; 7:491-497.
161. Khan MA, Dib J, Reddy IK. Statistical optimization of ketoprofen Eudragit S 100 coprecipitates to obtain controlled release tablets. Drug Dev Ind Pharm 1996; 22: 135-141.
162. Fassihi R, Fabian J, Sakr AM. Application of response surface methodology to design optimization in formulation of a typical controlled release system. Drugs made in Germany 1996; 39:122-126.
163. Mesiha MS, Rivera D. Factorial design of phenylpropanolamine prolonged release tablet formulations using fluid bed dryer granulator. Drug Dev Ind Pharm 1994; 20: 31-48.
164. Hirata M, Takayama K, Nagai T. Formulation optimization of sustained release tablet of chlorpheniramine maleate by means of extreme vertices design and simultaneous optimization technique. Chem Pharm Bull 1992; 40:741-746.
165. Ratsimbazafy V, Brossard C. Optimization of the release of theophylline derivatives from gelucire matrices. Pharm Acta Helv 1992; 67:166-171.
166. Perez-Marcos B, Iglesias R, Gomez-Amoza JL, Martinez-Pacheo R, Souto C, Conchiero R. Mechanical and drug release properties of atenolol-carbomer hydrophilic matrix tablets. J Control Release 1991; 17:267-276.
167. Ortigosa C, Guady D, Jacob M, Puech A. The role of gelucire in the availability of theophylline in semisolid matrix capsules. Pharm Acta Helv 1991; 66:311-315.
168. Ho C, Hwang GCC. Development of extended release solid dispersions of nonsteroidal antiinflammatory drugs with aqueous polymeric dispersions: optimization of drug release via a curve fitting technique. Pharm Res 1992; 9:206-210.
169. Karnachi AA, Khan MA. Box-Behnken design for the optimization of formulation variables of indomethacin coprecipitates with polymer mixtures. Int J Pharm 1996; 131:9-17.
170. Dangprasirt P, Ritthidej GC. Development of diclofenac sodium controlled
171. Yang Z, Zhu J. Study on preparation of pulsatile controlled-release tablets of theophylline. Zhongguo Yiyuan Yaoxue Zazhi 1998; 18:483-485.
172. Devay A, Uderszky J, Racz I. Formulation of effervescent tablets containing acetylsalicylic acid. Part 1. Investigation of granulation parameters. Acta Pharm Hung 1988; 58:97-100.
173. Rizk S, Duru C, Sabatier R, Jacob M, Puech A. Granulation process contribution to scleroglucan hydrophilic matrix formulation. Pharmazie 1995; 50:468-470.
174. Dredan J, Zelko R, Antal I, Bihari E, Racz I. Effect of particle size and coating level on the diffuse reflectance of wax matrices. J Pharm Pharmacol 1998; 50:139-142.
175. Timmins P, Delargy AM, Howard JR, Rowlands EA. Evaluation of the granulation of a hydrophilic matrix sustained release tablet. Drug Dev Ind Pharm 1991; 17: 531-550.
176. Furlanetto S, Maestrelli F, Orlandini S, Pinzauti S, Mura P. Optimization of dissolution test precision for a ketoprofen oral extended-release product. J Pharm Biomed Anal 2003; 32:159-165.
177. Baggesen S, Bechgaard H. In vitro evaluation of two controlled-release propoxyphene hydrochloride formulations. Influence of the composition of dissolution media on drug release. Pharm Acta Helv 1980; 55:312-315.
178. Allemann E, Leroux J-C, Gurny R. Polymeric nano- and microparticles for the oral delivery of peptides and peptidomimetics. Adv Drug Deliv Rev 1998; 34: 171-189.
179. Brannon-Peppas L. Recent advances on the use of biodegradable microparticles and nanoparticles in controlled drug delivery. Int J Pharm 1995; 116:1-9.
180. El-Banna HM, Efimova LS. Construction and use of factorial design in fluidized bed microencapsulation. Pharm Ind 1982; 44:641-645.
181. Ozyazici M, Sevgi F, Ertan G. Sustained-release dosage form of nicardipine hydrochloride: application of factorial design and effect of surfactant on release kinetics. Drug Dev Ind Pharm 1997; 23:761-770.
182. Karasulu HY, Ertan G, Guneri T. 3 (3) factorial design-based optimization of the formulation of nitrofurantoin microcapsules. Pharm World Sci 1996; 18:20-25.
183. Farivar M, Kas HS, Oner L, Hincal AA. Factorial design based optimization of the formulation of isosorbide-5-mononitrate microcapsules. J Micoencapsul 1993; 10: 309-317.
184. Oner L, Kas HS, Hincal AA. Studies on zinc sulphate microcapsules (2): application of factorial design. J Microencapsul 1988; 5:225-229.
185. Varshosaz J, Keihanfar M. Development and evaluation of sustained-release propranolol wax microspheres. J Microencapsul 2001; 18:277-284.
186. Luftensteiner CP, Viernstein H. Statistical experimental design based studies on placebo and mitoxantrone-loaded albumin microspheres. Int J Pharm 1998; 171: 87-99.
187. O'Hara P, Hickey AJ. Respirable PLGA microspheres containing rifampicin for the treatment of tuberculosis: manufacture and characterization. Pharm Res 2000; 17: 955-961.
188. Martinez-Sancho C, Herrero-Vanrell R, Negro S. Optimization of aciclovir poly (,-lactide-co-glycolide) microspheres for intravitreal administration using a factorial design study. Int J Pharm 2004; 273:45-56.
189. Sweet J, Danckwerts MP, Pillay V. Numerical optimization of PLGA microparticles for the enhancement of drug encapsulation efficiency. In: Proceedings of Annual Meeting of American Association of Pharmaceutical Scientists (AAPS); Maryland, USA, 2004; Abstract 002996.
190. Lambert O, Pfaeffle M, Ausborn M. Control of initial burst and release profile of protein loaded PLGA microparticles by adjusting composition of the polymer matrix and of the aqueous outer phase during manufacturing-a case study. In: Proceedings of Annual Meeting of American Association of Pharmaceutical Scientists (AAPS); Maryland, USA, 2004; Abstract 000401.
191. Ko JA, Park HJ, Park YS, Hwang SJ, Park JB. Chitosan microparticle preparation for controlled drug release by response surface methodology. J Microencapsul 2003; 20: 791-797.
192. Bayomi MA. Influence of polymers weight ratio and pH of polymers solution on the characteristics of chitosan-carboxymethyl cellulose microspheres containing theophylline. Boll Chim Farm 2003; 142:336-342.
193. Hariharan M, Price JC. Solvent, emulsifier and drug concentration factors in poly(D,L-lactic acid) microspheres containing hexamethylmelamine. J Microencapsul 2002; 19: 95-109.
194. Aberturas MR, Molpeceres J, Guzmán M, García F. Development of a new cyclosporine formulation based on poly(caprolactone) microspheres. J Microencapsul 2002; 19: 61-72.
195. Arica B, Ka HS, Orman MN, Hincal AA. Biodegradable bromocryptine mesylate microspheres prepared by a solvent evaporation technique. I: Evaluation of formulation variables on microspheres characteristics for brain delivery. J Microencapsul 2002; 19: 473-484.
196. Hu YQ, Guo JX, Wang LJ, Tan R, Zhen LY. Preparation and evaluation of insulin-loaded polylactide microspheres using factorial design. Drug Dev Ind Pharm 2000; 26:1309-1313.
197. Chawla V, Tiwary AK, Gupta S. Characterization of polyvinyl alcohol microspheres of diclofenac sodium: application of statistical design. Drug Dev Ind Pharm 2000; 26:675-680.
198. Gohel MC, Amin AF. Formulation design and optimization of modified-release microsphere of diclofenac sodium. Drug Dev Ind Pharm 1999; 25:247-251.
199. Gohel MC, Amin AF. Formulation optimization of controlled release diclofenac sodium microspheres using factorial design. J Control Release 1998; 51:115-122.
200. Lu B, Wu W. Optimization of preparation of dexamethasone acetate-loaded poly (D,L-lactide) microspheres by central composite design. Yaoxue Xuebao 1999; 34: 387-391.
201. Pean JM, Venier-Julienne MC, Filmon R, Sergent M, Phan-Tan-Luu R, Benoit JP. Optimization of HSA and NGF encapsulation yields in PLGA microparticles. Int J Pharm 1998; 166:105-115.
202. Gohel MC, Jani GK, Amin AF, Patel KV, Gupta SV. Application of classical experimental design for the development of theophylline microspheres. J Control Release 1997; 45:265-271.
203. Jani GK, Gohel MC. Effects of selected formulation parameters on the entrapment of diclofenac sodium in ethyl cellulose microspheres. J Control Release 1997; 43: 245-250.
204. Elkheshen S. Simplex lattice design for the optimization of the microencapsulation of a water soluble drug using poly(lactic acid) and poly(lactide-co-glycolide) copolymer. J Microencapsul 1996; 13:447-462.
205. Acikgöz M, Kas H, Orman M, Hincal A. Chitosan microspheres of diclofenac sodium: I. Application of factorial design and evaluation of release kinetics. J Micoencapsul 1996; 13:141-160.
206. Abu-Izza K, Garcia-Contreras L, Lu DR. Preparation and evaluation of sustained release AZT loaded microspheres: optimization of the release characteristics using response surface methodology. J Pharm Sci 1996; 85:144-149.
207. Lu DR, Abu-Izza K, Chen W. Optima: A windows-based program for computer-aided optimization of controlled-release dosage forms. Pharm Dev Technol 1996; 1: 405-414.
208. Celebi N, Erden N, Türkyilmaz A. The preparation and evaluation of salbutamol sulphate containing poly(lactic acid-co-glycolic acid) microspheres with factorial design-based studies. Int J Pharm 1996; 136:89-100.
209. Erden N, Celebi N. Factors influencing release of salbutamol sulphate from poly (lactide-co-glycolide) microspheres prepared by water-in-oil -in-water emulsion technique. Int J Pharm 1996; 137:57-66.
210. Chacón M, Berges L, Molpeceres J, Aberturas MR, Guzman M. Optimized preparation of poly D,L (lactic-glycolic) microspheres and nanoparticles for oral administration. Int J Pharm 1996; 141:81-91.
211. Chuo WH, Tsai TR, Hsu SH, Cham TM. Development of nifedipine-loaded albumin microspheres using a statistical factorial design. Int J Pharm 1996; 134:247-251.
212. Delgado A, Evora C, Llabres M. Optimization of 7-day release (in vitro) from DL-PLA methadone microspheres. Int J Pharm 1996; 134:203-211.
213. Soriano I, Evora C, Llabrés M. Preparation and evaluation of insulin-loaded poly (DL-lactide) microspheres using an experimental design. Int J Pharm 1996; 142:135-142.
214. Torres AI, Boisdron-Celle M, Benoît JP. Formulation of BCNU-loaded microspheres: influence of drug stability and solubility on the design of microencapsulation procedure. J Micoencapsul 1996; 13:41-51.
215. Wang YM, Sato H, Adachi I, Horikoshi I. Optimization of the formulation design of chitosan microspheres containing cisplatin. J Pharm Sci 1996; 85:1204-1210.
216. Mandal TK, Tenjarla S. Biodegradable microcapsules: optimization of formulation using factorial design. Pharm Sci 1995; 1:367-370.
217. Zeng XM, Martin GP, Marriott C. Tetrandrine delivery to the lung: optimization of albumin microsphere preparation by central composite design. Int J Pharm 1994; 109:135-145.
218. Hassan EE, Parish RC, Gallo JM. Optimized formulation of magnetic chitosan microspheres containing the anticancer agent, oxantrazole. Pharm Res 1992; 9:390-397.
219. Vural I, Kas HS, Oner L, Hincal AA. Cyclophosphamide loaded albumin microspheres. Part 4. Application of factorial design. STP Pharm Sci 1991; 1:318-320.
220. Gupta PK, Hung CT, Lam FC. Factorial design based optimization of the formulation of albumin microspheres containing adriamycin. J Microencapsul 1989; 6:147-160.
221. Nykamp G, Carstensen U, Muller BW. Jet milling-a new technique for microparticle preparation. Int J Pharm 2002; 242:79-86.
222. th Annual Meeting of Controlled Release Society; Scotland, UK, 2003; Abstract 212.
223. Narayan P, Marchant D, Wheatley MA. Optimization of spray drying by factorial design for production of hollow microspheres for ultrasound imaging. J Biomed Mater Res 2001; 56:333-341.
224. th Proc Int Symp Control Rel Bioact Mater 1999; 611-612.
225. Bibby DC, Davies NM, Tucker IG. Preparation and characterization of beta-cyclodextrin and poly(acrylic acid) microspheres. J Microencapsul 1998; 15:629-637.
226. Jones DS, Pearce KJ. Contribution of process variables to the entrapment efficiency of propranolol hydrochloride within ethylcellulose microspheres prepared by the solvent evaporation method as evaluated using a factorial design. Int J Pharm 1996; 131:25-31.
227. Zeng XM, Martin GP, Marriott C. Albumin microspheres as a means of drug delivery to the lung: analysis of the effects of process variables on particle sizes using factorial design methodology. Int J Pharm 1994; 107:205-210.
228. Öner L, Groves MJ. Optimization of conditions for preparing 2 to 5 micron range gelatin microparticles by using chilled dehydration agents. Pharm Res 1993; 10:621-626.
229. Agnihotri SA, Mallikarjuna NN, Aminabhavi TM. Recent advances on chitosan-based micro- and nanoparticles in drug delivery. J Control Release 2004; 100:5-28.
230. Zimmer A, Kreuter J. Microspheres and nanoparticles used in ocular delivery systems. Adv Drug Deliv Rev 1995; 16:61-73.
231. Vajdy M, O'Hagan DT. Microparticles for intranasal immunization. Adv Drug Deliv Rev 2001; 51:127-141.
232. Alonso MJ, Garcia ML, Espina M, Valls O, Egea MA. Aceclofenac-loaded poly(e-caprolactone) nanocapsules. Effect of coadjuvants on morphometrical properties and drug entrapment. Boll Chim Farm 2000; 139:114-119.
233. Molpeceres J, Aberturas MR, Chacon M, Bertges L, Guzman M. Stability of cyclosporin-loaded poly-sigma-caprolactone nanoparticles. J Microencapsul 1997; 14:777-787.
234. Molpeceres J, Guzman M, Aberturas MR, Chacon M, Berges L. Application of central composite designs to the preparation of polycaprolactone nanoparticles by solvent displacement. J Pharm Sci 1996; 85:206-213.
235. Calvo P, Sánchez A, Martínez J, López M, Calonge M, Pastor J, Alonso M. Polyester nanocapsules as new topical ocular delivery systems for Cyclosporin A. Pharm Res 1996; 13:311-315.
236. Wehrlé P, Magenheim B, Benita S. Influence of process parameters on the PLA nanoparticle size distribution, evaluated by means of factorial design. Eur J Pharm Sci 1995; 41:19-26.
237. Das S, Tucker I, Hill D, Ganguly N. Evaluation of poly(isobutylcyanoacrylate) nanoparticles for mucoadhesive ocular drug delivery. Part 1. Effect of formulation variables on physicochemical characteristics of nanoparticles. Pharm Res 1995; 12:534-540.
238. Losa C, Marchal Heussler L, Orallo F, Jato JLV, Alonso MJ. Design of new formulations for topical ocular administration: polymeric nanocapsules containing metipranolol. Pharm Res 1993; 10:80-87.
239. Carpignano R, Gasco MR, Morel S. Optimization of doxorubicine incorporation and of the yield of polybutylcyanoacrylate nanoparticles. Pharm Acta Helv 1991; 66:28-32.
240. Vandervoort J, Ludwig A. Biocompatible stabilizers in the preparation of PLGA nanoparticles: a factorial design study. Int J Pharm 2002; 238:77-92.
241. Müller B, Leuenberger H, Kissel T. Albumin microspheres as carriers for passive drug targeting: an optimized manufacturing technique. Pharm Res 1996; 13:32-37.
242. Cavalli R, Marengo E, Rodriguez L, Gasco MR. Effects of some experimental factors on the production process of solid lipid nanoparticles. Eur J Pharm Biopharm 1996; 42:110-115.
243. Julienne M, Alonso M, Amoza J, Benoit J. Preparation of poly(D,L lactide/glycolide) nanoparticles of controlled particle size distribution: application of experimental designs. Drug Dev Ind Pharm 1992; 18:1063-1077.
244. Alonso MJ, Sanchez A, Torres D, Seijo B, Vila-Jato JL. Joint effects of monomer and stabilizer concentration on physico-chemical characteristics of poly(butyl 2-cyanoacrylate) nanoparticles. J Microencapsul 1990; 7:517-526.
245. McLeod AD, Lam FC, Gupta PK, Hung CT. Optimized synthesis of polyglutaraldehyde nanoparticles using central composite design. J Pharm Sci 1988; 77:704-710.
246. Lian T, Ho RJY. Trends and developments in liposome drug delivery systems. J Pharm Sci 2001; 90:667-680.
247. Storm G, Crommelin DJA. Liposomes: quo vadis? Pharm Sci Technol Today 1998; 1:19-31.
248. Singh B, Mehta G, Kumar R, Bhatia A, Ahuja N, Katare OP. Design, development and optimization of nimesulide-loaded liposomal systems for topical application. Curr Drug Deliv 2005; 2:143-153.
249. Subramanian N, Yajnik A, Murthy RSR. Artificial neural network as an alternative to multiple regression analysis in optimizing formulation parameters of cytarabine liposomes. AAPS PharmSciTech 2004; 5: Article 4.
250. Mullaicharam AR, Murthy RSR. Formulation, optimization and stability of rifampicin niosomes. Indian Pharmacist 2004; 3:54-58.
251. Murthy RSR, Umrethia ML. Optimizaton of formulation parameters for the preparation of flutamide liposomes by 3(3) factorial 26-terms logit model. Pharm Dev Technol 2004; 9:1-9.
252. Rodriguez-Nogales JM, Perez-Mateos M, Busto MD. Application of experimental design to the formulation of glucose oxidase encapsulation by liposomes. J Chem Technol Biotechnol 2004; 79:700-705.
253. Luan L, Zhu J. Camptothecin niosomes prepared by central composite design. Zhong-guo Yiyao Gongye Zazhi 2003; 34:504-506.
254. Seth AK, Misra A. Mathematical modelling of preparation of acyclovir liposomes: reverse phase evaporation method. J Pharm Pharmaceut Sci 2002; 5:285-291.
255. Nagarsenker MS, Londhe VY. Optimization of liposomes containing sodium cromoglycate using factorial design: study of encapsulation efficiency and particle size. Indian Drugs 2001; 38:363-367.
256. Stensrud G, Sande SA, Kristensen S, Smistad G. Formulation and characterization of primaquine loaded liposomes prepared by a pH gradient using experimental design. Int J Pharm 2000; 198:213-228.
257. Loukas YL. A computer-based expert system designs and analyzes a 2(k-p) fractional factorial design for the formulation optimization of novel multicomponent liposomes. J Pharm Biomed Anal 1998; 17:133-140.
258. Loukas YL. A 2 (k-P) fractional factorial design via fold over: application to optimization of novel multicomponent vesicular system. Analyst 1997; 122:1023-1027.
259. Casals E, Gallardo M, Estelrich J. Factors influencing the encapsulation of thioguanine in DRV liposomes. Int J Pharm 1996; 143:171-177.
260. Loukas YL. Formulation optimization of novel multicomponent photoprotective liposomes by using response surface methodology. Analyst 1996; 121:279-284.
261. Foldvari M, Gesztes A, Mezei M, Cardinal L, Behl M. Topical liposomal local anesthetics: design, optimization and evaluation of formulations. Drug Dev Ind Pharm 1993; 19:2499-2517.
262. Mobed M, Chang TM. Adsorption of chitin derivatives onto liposomes: optimization of adsorption conditions. J Microencapsul 1998; 15:595-607.
263. Zadi B, Gregoriadis G. The use of factorial design and regression analysis for the prediction of vesicle characteristics in microfluidized liposomes. Eur J Pharm Sci 1996; 4:S173.
264. Moldavski N, Cohen S. Determinants of liposome partitioning in aqueous two-phase systems: evaluation by means of a factorial design. Biotechnol Bioeng 1996; 52:529-537.
265. Sibanda W, Pillay V, Danckwerts MP, Viljoen AM, van Vuuren S, Khan RA. Experimental design for the formulation and optimization of novel crosslinked oilispheres developed for in vitro site specific release of mentha piperita oil. AAPS PharmSciTech 2004; 5: Article 18.
266. Gasco MR, Morel S, Carpignano R. Optimization of the incorporation of deoxycorticosterone acetate in lipospheres. Eur J Pharm Biopharm 1992; 38:7-10.
267. Gandhi R, Kaul CL, Panchagnula R. Extrusion and spheronization in the development of oral controlled-release dosage forms. Pharm Sci Technol Today 1999; 2:160-170.
268. Vervaet C, Baert L, Remon JP. Extrusion-spheronisation: a literature review. Int J Pharm 1995; 116:131-146.
269. Ghebre-Sellassie I. Pharmaceutical Pelletization Technology. New York: Marcel Dekker, 1989.
270. Blanqué D, Sternagel H, Podczeck F, Newton JM. Some factors influencing the formation and in vitro drug release from matrix pellets prepared by extrusion/spheronization. Int J Pharm 1995; 119:203-211.
271. Chatchawalsaisin J, Podczeck F, Newton JM. The influence of chitosan and sodium alginate and formulation variables on the formation and drug release from pellets prepared by extrusion/spheronisation. Int J Pharm 2004; 275:41-60.
272. Podczeck F. The development and optimisation of tablet formulations using mathematical methods. In: Alderborn G, Nystrom C, editors. Pharmaceutical Powder Compaction Technology. New York: Marcel Dekker, 1995.
273. Surini S, Akiyama H, Morishita M, Nagai T, Takayama K. Release phenomena of insulin from an implantable device composed of a polyion complex of chitosan and sodium hyaluronate. J Control Release 2003; 90:291-301.
274. Turkoglu M, Varol H, Celikok M. Tableting and stability evaluation of enteric-coated omeprazole pellets. Eur J Pharm Sci 2004; 57:279-286.
275. Maheshwari M, Ketkar AR, Chauhan B, Patil VB, Paradkar AR. Preparation and characterization of ibuprofen-cetyl alcohol beads by melt solidification technique: effect of variables. Int J Pharm 2003; 261:57-67.
276. Kramar A, Turk S, Vrecer F. Statistical optimisation of diclofenac sustained release pellets coated with polymethacrylic films. Int J Pharm 2003; 256:43-52.
277. Lin AY, Muhammad NA, Pope D, Augsburger LL. A study of the effects of curing and storage conditions on controlled release diphenhydramine HCl pellets coated with Eudragit NE30D. Pharm Dev Technol 2003; 8:277-287.
278. Vaithiyalingam S, Khan MA. Optimization and characterization of controlled release multi-particulate beads formulated with a customized cellulose acetate butyrate dispersion. Int J Pharm 2002; 234:179-193.
279. Gupta VK, Assmus MW, Beckert TE, Price JC. A novel pH- and time-based multi-unit potential colonic drug delivery system. II. Optimization of multiple response variables. Int J Pharm 2001; 213:93-102.
280. Miron M, Bodea A, Leucuta SE. The statistical optimization of the preparation process for some enterosoluble pellets containing erythromycin as a base. Farmacia 2001; 49: 39-48.
281. Hamed E, Sakr A. Application of multiple response optimization technique to extended release formulations design. J Control Release 2001; 73:329-338.
282. Krogars K, Heinamaki J, Vesalahti J, Marvola M, Antikainen O, Yliruusi J. Extrusion-spheronization of pH-sensitive polymeric matrix pellets for possible colonic drug delivery. Int J Pharm 2000; 199:187-194.
283. Miron M, Bodea A, Leucuta SE. The statistical optimization in preparing erythromycin pellets. Farmacia 2000; 48:87-98.
284. Vojnovic D, Moneghini M, Perissutti B, Filipouic-Grcic J, Grabnar I. Preparation in high shear mixer of sustained release pellets by melt-pelletization. Int J Pharm 2000; 203:235-244.
285. Heau SH, Chew MY, Hileman GA, Durrani MJ, Gheyas F, Evans BA. Formulation and process considerations for beads containing carbopol® 974 P NF resin made by extrusion-spheronization. Int J Pharm 2000; 199:129-140.
286. Fekete R, Zelko R, Marton S, Racz I. Effect of the formulation parameters on the characteristics of pellets. Drug Dev Ind Pharm 1998; 24:1073-1076.
287. Zhou F, Vervaet C, Massart DL, Massart B, Remon JP. Optimization of the processing of matrix pellets based on the combination of waxes and starch using experimental design. Drug Dev Ind Pharm 1998; 24:353-358.
288. Takka S, Ocak OH, Acarturk F. Formulation and investigation of nicardipine HCl-alginate gel beads with factorial design-based studies. Eur J Pharm Sci 1998; 6:241-246.
289. Gouldson MP, Deasy PB. Use of cellulose ether containing excipients with microcrystalline cellulose for the production of pellets containing metformin hydrochloride by the process of extrusion-spheronization. J Microencapsul 1997; 14:137-153.
290. Bodea A, Leucuta SE. Optimization of propranolol hydrochloride sustained release pellets using a factorial design. Int J Pharm 1997; 154:49-57.
291. Palmieri GF, Wehrle P. Evaluation of ethylcellulose coated pellets optimized using the approach of Taguchi. Drug Dev Ind Pharm 1997; 23:1069-1077.
292. Hileman GA, Upadrashta SM, Neau SH. Drug solubility effect of predicting optimum conditions for extrusion and spheronization of pellets. Pharm Dev Technol 1997; 2:43-52.
293. Vertommen J, Kinget R. Influence of five selected processing and formulation variables on the release of riboflavin from pellets produced in a rotary processor. STP Pharm Sci 1996; 6:335-340.
294. Hassan EE, Eshra AG, Nada AH. Formulation of prolonged release lipid micropellets by emulsion congealing: optimization of ketoprofen entrapment and release. Int J Pharm 1995; 121:149-155.
295. Singh SK, Dodge J, Durrani MJ, Khan MA. Optimization and characterization of controlled release pellets coated with an experimental latex: 1. Anionic drug. Int J Pharm 1995; 125:243-255.
296. Ostberg T, Graffner C. Calcium alginate matrices for oral multiple unit administration: III. Influence of calcium concentration, amount of drug added and alginate characteristics on drug release. Int J Pharm 1994; 111:271-282.
297. Goskonda SR, Hileman GA, Upadrashta SM. Controlled release pellets by extrusion-spheronization. Int J Pharm 1994; 111:89-97.
298. Ostberg T, Vesterhus L, Graffner C. Calcium alginate matrices for oral multiple unit administration: II. Effect of process and formulation factors on matrix properties. Int J Pharm 1993; 97:183-193.
299. Takayama K, Nagai T. Novel computer optimization methodology for pharmaceutical formulations investigated by using sustained release granules of indomethacin. Chem Pharm Bull 1989; 37:160-167.
300. Zema L, Palugan L, Sangalli ME, Maroni A, Vecchio C, Giordano F, Gazzaniga A. Powder pelletization of a b-cyclodextrin/microcrystalline cellulose mixture in a fluid bed rotor granulator: sequential statistical optimization of the process. Acta Technologiae et Legis Medicamenti 2001; 12:1-14.
301. Paterakis PG, Korakianiti ES, Dallas PP, Rekkas DM. Evaluation and simultaneous optimization of some pellets characteristics using a 3(3) factorial design and the desirability function. Int J Pharm 2002; 248:51-60.
302. Chukwumezie BN, Wojcik M, Malak P, D'Amico F, Adeyeye MC. Factorial design in the spheronization of ibuprofen microparticulates using the rotor disk fluid-bed technology. Pharm Dev Technol 2004; 9:49-62.
303. Santos H, Veiga F, Pina M, Podczeck F, Sousa J. Physical properties of chitosan pellets produced by extrusion-spheronisation: influence of formulation variables. Int J Pharm 2002; 246:153-169.
304. Flanner HH, Vesey CF, Loehe JR. Dissolution fit factors as response variables in statistically designed experiments. Dissolution Technol 2001; 8:13-18.
305. Rashid HA, Heinamaki J, Antikainen O, Yliruusi J. Influence of the centrifugal granulating process on the properties of layered pellets. Eur J Pharm Biopharm 2001; 51:227-234.
306. Thiesa R, Kleinebudde P. Melt pelletisation of a hygroscopic drug in a high shear mixer part 1. Influence of process variables. Int J Pharm 1999; 188:131-143.
307. Abuzarur-Aloul R, Gjellan K, Sjolund M, Graffner C. Critical dissolution tests of oral systems based on statistically designed experiments. II. In vitro optimization of screened variables on ER-coated spheres for the establishment of an in vitro/in vivo correlation. Drug Dev Ind Pharm 1998; 24:203-212.
308. Vertommen A, Kinget R. The influence of five selected processing and formulation variables on the particle size, particle size distribution, and friability of pellets produced in a rotary processor. Drug Dev Ind Pharm 1997; 23:39-46.
309. Heng PWS, Wan LCS, Tan YTF. Optimization of spheroid production by centrifugal rotary processing. Int J Pharm 1996; 143:107-112.
310. Sonaglio D, Bataille B, Ortigosa C, Jacob M. Factorial design in the feasibility of producing Microcel MC 101 pellets by extrusion/spheronization. Int J Pharm 1995; 115:53-60.
311. Shah RD, Kabadi M, Pope DG, Augsburger LL. Physico-mechanical characterization of the extrusion-spheronization process. Part 2. Rheological determinants for successful extrusion and spheronization. Pharm Res 1995; 12:496-507.
312. Wehrlé P, Palmieri GF, Stamm A. Taguchi's performance statistic to optimize theophylline beads production in a high-speed granulator. Drug Dev Ind Pharm 1994; 20:2823-2843.
313. Hutchings D, Kuzmak B, Sakr A. Processing considerations for an EC latex coating systems: influence of curing time and temperature. Pharm Res 1994; 11:1474-1478.
314. Hileman GA, Goskonda SR, Spalitto AJ, Upadrashta SM. Response surface optimization of high dose pellets by extrusion and spheronization. Int J Pharm 1993; 100:71-79.
315. Shirakura O, Yamada M, Hashimoto M, Ishimaru S, Takayama K, Nagai T. Effect of amount and composition of granulating solution on physical characteristics of tablets. Drug Dev Ind Pharm 1992; 18:1099-1110.
316. Lalla JK, Bhat SU. Non pareil seed: 23! Factorial approach to optimization of coating for pellet preparation: coating pan vs dish pelletizer. Indian Drugs 1992; 29:527-536.
317. Jozwiakowski MJ, Jones DM, Franz RM. Charaterization of a hot-melt fluid bed coating process for fine granules. Pharm Res 1990; 7:1119-1126.
318. Gajdos B. Rotor granulators-evaluation of process technology for pelletizing using a factorial experimental design. Pharm Ind 1983; 45:722-728.
319. Malinowski HJ, Smith WE. Effects of spheronization process variables on selected tablet properties. J Pharm Sci 1974; 63:285-288.
320. Malinowski HJ, Smith WE. Use of factorial design to evaluate granulations prepared by spheronization. J Pharm Sci 1975; 64:1688-1692.
321. Singh BN, Kim KH. Floating drug delivery systems: an approach to oral controlled drug delivery via gastric retention. J Control Release 2000; 63:235-259.
322. Whitehead L, Fell JT, Collett JH, Sharma HL, Smith A-M. Floating dosage forms: an in vivo study demonstrating prolonged gastric retention. J Control Release 1998; 55:3-12.
323. Hou SY, Cowles VE, Berner B. Gastric retentive dosage forms: a review. Crit Rev Tner Drug Carrier Syst 2003; 20:459-497.
324. Reddy LH, Murthy RS. Floating dosage systems in drug delivery. Crit Rev Ther Drug Carrier Syst 2002; 19:553-585.
325. Dave BS, Amin AF, Patel MM. Gastroretentive drug delivery system of ranitidine hydrochloride: formulation and in vitro evaluation. AAPS PharmSciTech 2004; 5: article 34.
326. Li S, Lin S, Daggy BP, Mirchandani HL, Chien YW. Effect of HPMC and carbopol on the release and floating properties of gastric floating drug delivery system using factorial design. Int J Pharm 2003; 253:13-22.
327. Li S, S. L, Daggy BP, Mirchandani HL, Chien YW. Effect of formulation variables on the floating properties of gastric floating drug delivery system. Drug Dev Ind Pharm 2002; 28:783-793.
328. Li S, Lin S, Chien YW, Daggy BP, Mirchandani HL. Statistical optimization of gastric floating system for oral controlled delivery of calcium. AAPS PharmSciTech 2001; 2: article 1.
329. Chueh H, Zia H, Rhodes C. Optimization of sotalol floating and bioadhesive extended release tablet formulations. Drug Dev Ind Pharm 1995; 21:1725-1747.
330. Menon A, Ritschel WA, Sakr A. Development and evaluation of a monolithic floating dosage form for furosemide. J Pharm Sci 1994; 83:239-245.
331. Verma RK, Mishra B, Garg S. Osmotically controlled oral drug delivery. Drug Dev Ind Pharm 2000; 26:695-708.
332. Kaushal AM, Garg S. An update on osmotic drug delivery patents. Pharm Technol 2003; 38-44, 97.
333. Wu T, Pan W, Chen J, Zhang R. Formulation optimization technique based on artificial neural network in salbutamol sulfate osmotic pump tablets. Drug Dev Ind Pharm 2000; 26:211-215.
334. Wu T, Pan W, Chen J, Zhang R. Preparation of salbutamol sulfate osmotic pump tablets by simultaneous optimization technique. Yaoxue Xuebao 2000; 35:617-621.
335. Sastry SV, Khan MA. Aqueous-based polymeric dispersion: face-centered cubic design for the development of atenolol gastrointestinal therapeutic system. Pharm Dev Technol 1998; 3:423-432.
336. Sastry SV, Reddy IK, Khan MA. Atenolol gastrointestinal therapeutic system: optimization of formulation variables using response surface methodology. J Control Release 1997; 45:121-130.
337. Jensen JL, Appel LE, Clair JH, Zentner GM. Variables that affect the mechanism of drug release from osmotic pumps coated with acrylate/methacrylate copolymer latexes. J Pharm Sci 1995; 84:530-533.
338. Appel EA, Clair JH, Zentner GM. Formulation and optimization of a modified microporous cellulose acetate latex coating for osmotic pumps. Pharm Res 1992; 9:1664-1667.
339. Woodley J. Bioadhesion: New possibilities for drug administration? Clin Pharmacokinet 2001; 40:77-84.
340. Haas J, Lehr CM. Developments in the area of bioadhesive drug delivery systems. Expert Opin Biol Ther 2002; 2:287-298.
341. Lavelle EC. Targeted delivery of drugs to the gastrointestinal tract. Crit Rev Ther Drug Carrier Syst 2001; 18:341-386.
342. Singh B, Chakkal SK, Ahuja N. Computer-aided design, development and optimization of controlled release mucoadhesive formulations of atenolol. In: Proceedings of National Seminar on Pharmaceutics in the Light of Drug Delivery Challenges; Chandigarh, India, 2003; Abstract P11.
343. th Annual Meeting of Controlled Release Society; Seoul, Korea, 2002; Abstract 258.
344. Singh B, Ahuja N. Development of controlled-release buccoadhesive hydrophilic matrices of diltiazem hydrochloride: optimization of bioadhesion, dissolution, and diffusion parameters. Drug Dev Ind Pharm 2002; 28:431-442.
345. Uraizee SA, McPhillips AM, Ritschel WA, Sakr A. Development of a targeted mucoadhesive drug delivery system for the peroral administration of insulin. Drugs Made in Germany 2000; 43:41-44.
346. Uraizee SA, McPhillips AM, Ritschel WA, Sakr A. Development of a targeted mucoadhesive drug delivery system for the peroral administration of insulin. Pharm Ind 1999; 61:569-573.
347. Elkheshen SA, Hosny EA. Bioadhesive matrix as a controlled-release dosage form for verapamil hydrochloride: effect of mixing polymers on water uptake of the matrix and the drug release rate using a simplex lattice design. Pharm Ind 1999; 61:666-670.
348. Chu JS, Chandrasekharan R, Amidon GL, Weiner ND, Goldberg AH. Viscometric study of polyacrylic acid systems as mucoadhesive sustained-release gels. Pharm Res 1991; 8:1408-1412.
349. Chu JS, Amidon GL, Weiner ND, Goldberg AH. Mixture experimental design in the development of a mucoadhesive gel formulation. Pharm Res 1991; 8:1401-1407.
350. Berba J, Benakar U. Clinical efficacy of current transdermal drug delivery systems: a retrospective evaluation. Am Pharm 1990; 11:33-41.
351. Wester RC, Maibach HI. Percutaneous absorption of drugs. Clin Pharmacokinet 1992; 23:235-266.
352. Guy RH, Hadgraft J. The effect of penetration enhancers on the kinetics of percutaneous absorption. J Control Release 1987; 5:43-51.
353. Giannakou SA, Dallas PP, Rekkas DM, Choulis NH. In vitro evaluation of nimodipine permeation through human epidermis using response surface methodology. Int J Pharm 2002; 241:27-34.
354. Wolff H-M. Optimal process design for the manufacture of transdermal drug delivery systems. Pharm Sci Technol Today 2000; 3:173-181.
355. Simon L, Fernandes M, Otto H. Neural network-based prediction and optimization of estradiol release from ethylene-vinyl acetate membranes. Comput Chem Eng 2004; 28:2407-2419.
356. Dimas DA, Dallas PP, Rekkas DM. Use of an 8132 asymmetrical factorial design for the in vitro evaluation of ondansetron permeation through human epidermis. Pharm Dev Technol 2004; 9:39-48.
357. Devi KV, Saisivam S, Maria GR, Deepti PU. Design and evaluation of matrix diffusion controlled transdermal patches of verapamil hydrochloride. Drug Dev Ind Pharm 2003; 29:495-503.
358. Manna A, Ghosh I, Sen N, Thakur RS, Ghosh LK, Gupta BK. Statistical optimization of transdermal drug delivery system of terbutaline sulfate by factorial analysis. Boll Chim Farm 2000; 139:34-40.
359. Nagels KH, Wolff H-M, Merkle HP. Optimization of HMPSA formulations for transdermal bupranolol delivery by means of a {3,2} simplex-lattice design. Proc Int Symp Control Release Bioact Mater 1993; 20:426-427.
360. st Indian Science Congress; Chandigarh, India, 2004; Abstract A4.
361. Cafaggi S, Leardi R, Parodi B, Caviglioli G, Bignardi G. An example of application of a mixture design with constraints to a pharmaceutical formulation. Chemom Intell Lab Syst 2003; 65:139-147.
362. Kandimalla KK, Kanikkannan N, Singh M. Optimization of a vehicle mixture for the transdermal delivery of melatonin using artificial neural networks and response surface method. J Control Release 1999; 61:71-82.
363. Takayama K, Fujikawa M, Obata Y, Morishita M, Nagai T. Optimization of pharmaceutical formulations based on artificial neural networks. Yakuzaigaku 2004; 64: 2-12.
364. Giannakou SA, Dallas PP, Rekkas DM, Choulis NH. Development and in vitro evaluation of nimodipine transdermal formulations using factorial design. Pharm Dev Technol 1998; 3:517-525.
365. Takahara J, Takayama K, Isowa K, Nagai T. Multi-objective simultaneous optimization based on an artificial neural network in a ketoprofen hydrogel formula containing o-ethylmenthol as a percutaneous absorption enhancer. Int J Pharm 1997; 158: 203-210.
366. Liu CH, Ho HO, Hsieh MC, Sokoloski TD, Sheu MT. Studies on the in-vitro percutaneous penetration of indomethacin from gel systems in hairless mice. J Pharm Pharmacol 1995; 45:365-372.
367. Giannakou S, Dallas P, Rekkas D, Choulis N. Development and in vitro evaluation of nitrendipine transdermal formulations using experimental design techniques. Int J Pharm 1995; 125:7-15.
368. Ho HO, Huang FC, Sokoloski TD, Sheu MT. Influence of cosolvents on the in vitro percutaneous penetration of diclofenac sodium from a gel system. J Pharm Pharmacol 1994; 46:636-642.
369. Levison KK, Takayama K, Isowa K, Okabe K, Nagai T. Formulation optimization of indomethacin gels containing a combination of three kinds of cyclic monoterpenes as percutaneous penetration enhancers. J Pharm Sci 1994; 83:1367-1372.
370. Takayama K, Nagai T. Simultaneous optimization for several characteristics concerning percutaneous absorption and skin damage of ketoprofen hydrogels containing d limonene. Int J Pharm 1991; 74:115-126.
371. Singh P, Maibach HI. Iontophoresis: an alternative to the use of carriers in cutaneous drug delivery. Adv Drug Deliv Rev 1996; 18:379-394.
372. Nair V, Pillai O, Poduri R, Panchagnula R. Transdermal iontophoresis. Part I: Basic principles and considerations. Methods Find Exp Clin Pharmacol 1999; 21:139-151.
373. Riviere JE, Heit MC. Electrically-assited transdermal drug delivery. Pharm Res 1997; 14:687-697.
374. Lim CP, Quek SS, Peh KK. Prediction of drug release profiles using an intelligent learning system: an experimental study in transdermal iontophoresis. J Pharm Biomed Anal 2003; 31:159-168.
375. Huang YY, Wu SM, Wang CY. Response surface method: a novel strategy to optimize iontophoretic transdermal delivery of thyrotrophin releasing hormone. Pharm Res 1996; 13:547-552.
376. Huang Y, Wu S, Wang C, Jiang T. Response surface method as an approach to optimization of iontophoretic transdermal delivery of pilocarpine. Int J Pharm 1996; 129:41-50.
377. Vanbever R, Le Boulenge E, Preat V. Transdermal delivery of fentanyl by electroporation. Part 1. Influence of electrical factors. Pharm Res 1996; 13:559-565.
378. Dimas DA, Dallas PP, Rekkas DD, Choulis NH. Effect of several factors on the mechanical properties of pressure-sensitive adhesives used in transdermal therapeutic systems. AAPS PharmSciTech 2000; 1: article 16.
379. Lipp R, Heimann G. Statistical approach to optimization of drying conditions for a transdermal delivery system. Drug Dev Ind Pharm 1996; 22:343-348.
380. Horter D, Dressman JB. Influence of physicochemical properties on dissolution of drugs in the gastrointestinal tract. Adv Drug Deliv Rev 2001; 46:75-87.
381. Habib MJE. Pharmaceutical Solid Dispersion Technology. Pennysylvania: Technomic Publishing Co., 2001.
382. Charman WN. Lipids, lipophilic drugs, and oral drug delivery-some emerging concepts. J Pharm Sci 2000; 89:967-978.
383. Gohel MC, Patel M, Amin AF, Agrawal R, Dave R, Bariya N. Formulation design and optimization of mouth dissolve tablets of nimesulide using vacuum drying technique. AAPS PharmSciTech 2004; 5:Article 36.
384. Lee KJ, Kang A, Delfino JJ, West TG, Chetty D, Monkhouse DC, Yoo J. Evaluation of critical formulation factors in the development of a rapidly dispersing captopril oral dosage form. Drug Dev Ind Pharm 2003; 29:967-979.
385. Schiermeier S, Schmidt PC. Fast dispersible ibuprofen tablets. Eur J Pharm Sci 2002; 15:295-305.
386. Weon KY, Lee KT, Seo SH. Optimization study on the formulation of roxithromycin dispersible tablet using experimental design. Arch Pharm Res 2000; 23:507-512.
387. Ngo TH, Vertommen J, Kinget R. Formulation of artemisinin tablets. Int J Pharm 1997; 146:271-274.
388. Rekhi GS, Eddington ND, Fossler MJ, Schwartz P, Lesko LJ, Augsburger LL. Evaluation of in vitro release rate and in vivo absorption characteristics of four metoprolol tartrate immediate-release tablet formulations. Pharm Dev Technol 1997; 2:11-24.
389. Khattab I, Menon A, Sakr A. Study of the effect of disintegrant distribution ratio on tablet characteristics using a central composite design. Eur J Pharm Biopharm 1993; 39:260-263.
390. Fenyvesi E, Takayama K, Szejtli J, Nagai T. Evaluation of cyclodextrin polymer as an additive for furosemide tablets. Chem Pharm Bull 1984; 32:670-677.
391. Bi Y, Yonezawa Y, Sunada H. Rapidly disintegrating tablets prepared by the wet compression method: mechanism and optimization. J Pharm Sci 1999; 88:1004-1010.
392. Bi Y, Sunada H, Yonezawa Y, Danjo K. Evaluation of rapidly disintegrating tablets prepared by a direct compression method. Drug Dev Ind Pharm 1999; 25:571-581.
393. Pouton CW. Self-emulsifying drug delivery systems: assessment of the efficiency of emulsification. Int J Pharm 1985; 27:335-348.
394. Patil P, Joshi P, Paradkar A. Effect of formulation variables on preparation and evaluation of gelled self-emulsifying drug delivery system (SEDDS) of ketoprofen. AAPS PharmSciTech 2004; 5: article 42.
395. Gao P, Witt MJ, Haskell RJ, Zamora KM, Shifflett JR. Application of a mixture experimental design in the optimization of a self-emulsifying formulation with a high drug load. Pharm Dev Technol 2004; 9:301-309.
396. Magee GA, Rench J, Gibbon B, Luscombe C. Bile salt/lecithin mixed micelles optimized for the solubilization of a poorly soluble steroid molecule using statistical experimental design. Drug Dev Ind Pharm 2003; 29:441-450.
397. Nazzal S, Nutan M, Palamakula A, Shah R, Zaghloul AA, Khan MA. Optimization of a self-nanoemulsified tablet dosage form of ubiquinone using response surface methodology: effect of formulation ingredients. Int J Pharm 2002; 240:103-114.
398. Nazzal S, Khan MA. Response surface methodology for the optimization of ubiquinone self-nanoemulsified drug delivery system. AAPS PharmSciTech 2002; 3: Article 3.
399. Serajuddin ATM. Solid dispersion of poorly water soluble drugs: early promises, subsequent problems, and recent breakthroughs. J Pharm Sci 1999; 88:1058-1066.
400. Gohel MC, Patel LD. Processing of nimesulide-PEG 400-PG-PVP solid dispersions: preparation, characterization, and in vitro dissolution. Drug Dev Ind Pharm 2003; 29: 299-310.
401. Singh B, Singla YP, Dhiman A, Ahuja N. Formulation, optimization and characterization of flurbiprofen solid dispersions using biodegradable polymers. In: Proceedings of National Seminar on Pharmaceutics in the Light of Drug Delivery Challenges; Chandigarh, India, 2003; Abstract P1.
402. Rambali B, Verreck G, Baert L, Massart BL. Itraconazole formulation studies of the melt-extrusion process with mixture design. Drug Dev Ind Pharm 2003; 29:641-652.
403. th Annual Meeting of Controlled Release Society; Seoul, Korea, 2002; Abstract 663.
404. Gohel MC, Patel LD. Improvement of nimesulide dissolution from solid dispersions containing croscarmellose sodium and aerosil 200. Acta Pharm 2002; 52:227-241.
405. Gohel MC, Patel LD. Improvement of nimesulide dissolution by a co-grinding method using surfactants. Pharm Pharmacol Commun 2000; 6:433-440.
406. Nagarsenker MS, Garad SD. Physical characterization and optimization of dissolution parameters of prochlorperazine maleate coevaporates. Int J Pharm 1998; 160: 251-255.
407. Lee J-W, Park E-S, Chi S-C. Formulation optimization of the tablet prepared with solid dispersion of biphenyl dimethyl dicarboxylate with poloxamer. Yakche Hakhoechi 1998; 28:267-274.
408. Ferrari F, Bertoni M, Bonferoni C, Rossi S, Caramella C, Bolhuis G. Dissolution enhancement of an insoluble drug by physical mixture with a superdisintegrant: optimization with a simplex lattice design. Pharm Dev Technol 1996; 1:159-164.
409. Bonelli D, Clementi S, Ebert C, Lovrecich M, Rubessa F. Chemometric modelling of dissolution rates of griseofulvin from solid dispersions with polymers. Drug Dev Ind Pharm 1989; 15:1375-1391.
410. Takayama K, Imaizumi H, Nambu N, Nagai T. Mathematical optimization of formulation of indomethacin-poly(vinylpyrrolidone)-methyl cellulose solid dispersions by the sequential unconstrained minimization technique. Chem Pharm Bull 1985; 33: 292-300.
411. Takai T, Takayama K, Nambu N, Nagai T. Optimum formulation of griseofulvin/hydroxypropylcellulose solid dispersions with desirable dissolution properties. Chem Pharm Bull 1984; 32:1942-1947.
412. Frontini R, Mielck JB. Interactions between bendroflumethiazide and water soluble polymers. Part 2. Factors promoting drug-polymer association. Eur J Pharm Sci 1997; 43:309-313.
413. Chourasia MK, Jain SK. Influence of physicochemical properties on dissolution of drugs in the gastrointestinal tract. J Pharm Pharmaceut Sci 2003; 6:33-66.
414. Yang L, Chu JS, Fix JA. Colon-specific drug delivery: new approaches and in vitro/in vivo evaluation. Int J Pharm 2002; 235:1-15.
415. Liu L, Fishman ML, Kost J, Hicks KB. Pectin-based systems for colon-specific drug delivery via oral route. Biomaterials 2003; 24:3333-3343.
416. Leopold CS. Coated dosage forms for colon-specific drug delivery. Pharm Sci Technol Today 1999; 2:197-204.
417. El-Gibaly I. Oral delayed-release system based on Zn-pectinate gel (ZPG) microparticles as an alternative carrier to calcium pectinate beads for colonic drug delivery. Int J Pharm 2002; 232:199-211.
418. Torchilin VP. Drug targeting. Eur J Pharm Sci 2000; 11:S81-S91.
419. Kaur IP, Kanwar M. Ocular preparations: the formulation approach. Drug Dev Ind Pharm 2002; 28:473-493.
420. Ugwoke MI, Verbeke N, Kinget R. The biopharmaceutical aspects of nasal mucoadhesive drug delivery. J Pharm Pharmacol 2001; 53:3-21.
421. Behl CR, Pimplaskar HK, Sileno AP, Xia WJ, Gries WJ, deMeireles JC, Romeo VD. Optimization of systemic nasal drug delivery with pharmaceutical excipients. Adv Drug Deliv Rev 1998; 29:117-133.
422. Labiris NR, Dolovich MB. Pulmonary drug delivery. Part II: The role of inhalant delivery devices and drug formulations in therapeutic effectiveness of aerosolized medications. Br J Clin Pharmacol 2003; 56:600-612.
423. Malcolmson RJ, Embleton JK. Dry powder formulations for pulmonary delivery. Pharm Sci Technol Today 1998; 1:394-398.
424. McCallion ONM, Taylor KMG, Bridges PA, Thomas M, Taylor AJ. Jet nebulisers for pulmonary drug delivery. Int J Pharm 1996; 130:1-11.
425. Juslin L, Antikainen O, Merkku P, Yliruusi J. Droplet size measurement. Part 2. Effect of three independent variables on parameters describing the droplet size distribution from a pneumatic nozzle studied by multilinear stepwise regression analysis. Int J Pharm 1995; 123:257-264.
426. Fedina LT, Zelko R, Fedina LI, Szabados ZS, Szanto M, Vakulya G. The effect of surfactant and suspending agent concentration on the effective particle size of metered-dose inhalers. J Pharm Pharmacol 1997; 49:1175-1177.
427. Iwata M, Takayama K, Machida Y, Shirotake S, Nagai T. Formulation optimization of progesterone suppository using mixtures of witepsol and ethylene vinyl acetate copolymer as a base. Byoin Yakugaku 1995; 21:269-275.
428. Golovkin VA, Lukash EP, Fadeicheva AG, Groshovyi TA, Mokhort NA. Optimization of the formulation of suppositories containing mephenamic acid and their biopharmaceutical study. Farmatsiya 1978; 27:16-19.
429. Golovkin VA, Groshovyi TA, Slobodianiuk NN. Technology optimization and a study of rectal drug forms. I. The use of experimental design in the technology of pediatric molded suppositories made of sodium mefenaminate. Farm Zh 1976; 4:51-54.
430. Iwata M, Ito S, Takayama K, Machida Y, Nagai T. Formulation study of adriamycin creams with addition of medroxyprogesterone acetate. Byoin Yakugaku 1988; 14: 262-266.
431. Contreras MD, Sanchez R. Application of a factorial design to the study of specific parameters of a carbopol ETD 2020 gel. Part I. Viscoelastic parameters. Int J Pharm 2002; 234:139-147.
432. Nangia A, Lam F, Hung CT. Formulation optimization of a hydrocolloid dressing. Drug Dev Ind Pharm 1990; 16:2109-2123.
433. Nielloud F, Mestres JP, Fortune R, Draussin S, Marti-Mestres G. Formulation of oil-in-water submicron emulsions in the dermatological field using experimental design. Polymer Int 2003; 52:610-613.
434. 4 factorial design. Drug Dev Ind Pharm 1996; 22:623-630.
435. Elkheshen SA, Abd El-Gawad NA, Badawi AA. Factorial design and computer optimization of a reconstitutable suspension of erythromycin ethylsuccinate. Pharm Ind 1997; 59:439-443.
436. Prinderre P, Piccerelle P, Cauture E, Kalantzis G, Joachim J. Formulation and evaluation of o/w emulsions using experimental design. Int J Pharm 1998; 163:73-79.
437. Packhaeuser CB, Schnieders J, Oster CG, Kissel T. In situ forming parenteral drug delivery systems: an overview. Eur J Pharm Biopharm 2004; 58:445-455.
438. Stephens D, Li LC, Pec E, Robinson D. A statistical experimental approach to cosolvent formulation of a water-insoluble drug. Drug Dev Ind Pharm 1999; 25:961-965.
439. Jumaa M, Kleinebudde P, Müller BW. Mixture experiments with the oil phase of parenteral emulsions. Eur J Pharm Biopharm 1998; 46:161-167.
440. Kagkadis KA, Rekkas DM, Dallas PP, Choulis NH. A freeze-dried injectable form of flurbiprofen: development and optimisation using response surface methodology. Int J Pharm 1998; 161:87-94.
441. Kagkadis KA, Rekkas DM, Dallas PP, Choulis NH. Freeze dried injectable form of ibuprofen: development and optimization using response surface methodology. PDA J Pharm Sci Technol 1996; 50:317-323.
442. Pillai O, Nair V, Poduri R, Panchagnula R. Transdermal iontophoresis. Part II: peptide and protein delivery. Methods Find Exp Clin Pharmacol 1999; 21:229-240.
443. Cleland JL, Daugherty A, Mrsny R. Emerging protein delivery methods. Curr Opin Biotechnol 2001; 12:212-219.
444. Tseng W-C, Huang L. Liposome-based gene therapy. Pharm Sci Technol Today 1998; 1:206-213.
445. Page DT, Cudmore S. Innovations in oral gene delivery: challenges and potentials. Drug Discov Today 2001; 6:92-101.
446. Sershen S, West J. Implantable, polymeric systems for modulated drug delivery. Adv Drug Deliv Rev 2002; 54:1225-1235.
447. Panyam J, Labhasetwar V. Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Adv Drug Deliv Rev 2003; 55:329-347.
448. Sinha VR, Trehan A. Biodegradable microspheres for protein delivery. J Control Release 2003; 90:261-280.
449. Hussain A, Arnold JJ, Khan MA, Ahsan F. Absorption enhancers in pulmonary protein delivery. J Control Release 2004; 94:15-24.
450. Birchall JC, Waterworth CA, Luscombe C, Parkins DA, Gumbleton M. Statistical modelling of the formulation variables in non-viral gene delivery systems. J Drug Target 2001; 9:169-184.
451. Cherng J-Y, Talsma H, Verrijk R, Crommelin DJA, Hennink WE. The effect of formulation parameters on the size of poly((2-dimethylamino)ethyl methacrylate)-plasmid complexes. Eur J Pharm Biopharm, 1999; 47:215-224.
452. Branchu S, Forbes RT, York P, Nyqvist H. Central composite design to investigate the thermal stabilization of lysozyme. Pharm Res 1999; 16:702-708.
453. Tomuta I, Leucuta SE. Use of experimental design for identifying the most important formulation and technological variables in pelletization by powder layering. Drug Deliv Sci Technol 2004; 14:215-221.
454. Agyralides GG, Dallas PP, Rekkas DM. Development and in vitro evaluation of furosemide transdermal formulations using experimental design techniques. Int J Pharm 2004; 281:35-43.
455. Loukas YL. A Plackett-Burman screening design directs the efficient formulation of multicomponent DRV liposomes. J Pharm Biomed Anal 2001; 26:255-263.
456. Vaithiyalingam S, Reddy IK, Khan MA. Formulation of controlled release beads containing verapamil HCl: screening of process and formulation variables. In: Proceedings of 28th Int Symp Control Release Bioact Mater; California, USA, 2001; 836-837.
457. Khan MA, Sastry SV, Vaithiyalingam SR, Agarwal V, Nazzal S, Reddy IK. Captopril gastrointestinal therapeutic system coated with cellulose acetate pseudolatex: evaluation of main effects of several formulation variables. Int J Pharm 2000; 193:147-156.
458. Hwang RC, Gemoules MK, Ramlose DS, Thomasson CE. Systematic formulation optimization process for a generic pharmaceutical tablet. Pharm Technol 1998; 22:48-64.
459. Sastry SV, Khan MA. Aqueous based polymeric dispersion: Plackett-Burman design for screening of formulation variables of atenolol gastrointestinal therapeutic system. Pharm Acta Helv 1998; 73:105-112.
460. Li JZ, Rekhi GS, Augsburger LL, Shangraw RF. The role of intra- and extragranular microcrystalline cellulose in tablet dissolution. Pharm Dev Technol 1996; 1:343-355.
461. Wambolt EA, Sakr A. Spray dried controlled release tablet granulations: effect of formulation variables on granulation and tablet characteristics. Boll Chim Farm 1995; 134:263-274.
462. Hileman GA, Goskonda SR, Spalitto AJ, Upadrashta SM. Factorial approach to high dose product development by an extrusion/spheronization process. Drug Dev Ind Pharm 1993; 19:483-491.
463. 6study design was used to investigate the influence of process variables and spheronizer on the shape and size distribution of pellets. Int J Pharm 1993; 96:217-223.
464. Hellen L, Yliruusi J, Kristofferson E. Process variables of instant granulator and spheronizer. II. Size and size distribution of pellet. Int J Pharm 1993; 96:205-216.
465. Hellen L, Yliruusi J, Merkku P, Kristofferson E. Process variables of instant granulator and spheronizer. 1. Physical properties of granules, extrudate and pellet. Int J Pharm 1993; 96:197-204.
466. Vojnovic D, Chicco D. Mixture experimental design applied to solubility predictions. Drug Dev Ind Pharm 1997; 23:639-645.
467. Chicco D, Moneghini M, Rubessa F, Vojnovic D. Mixture design applied to solubility predictions and pharmaceutical formulation. Farm Vestn 1995; 46:189-190.
468. Bolton S, Reinstein J, Alobe O, Vicks R. Application of factorial designs in kinetic studies: hydrolysis of benzylpenicillin solutions. Int J Pharm Technol Prod Manuf 1984; 5:6-12.
469. Bolton S. Factorial designs in pharmaceutical stability studies. J Pharm Sci 1983; 72: 362-366.
470. Bos CE, Bolhuis GK, Lerk CF, De Boer JH, Duineveld CAA, Smilde AK, Doornbos DA. Optimization of direct compression tablet formulations for use in tropical countries. Drug Dev Ind Pharm 1991; 17:2477-2496.
471. Buffo R, Reineccius G. Optimization of gum acacia/modified starch/maltodextrin blends for the spray drying of flavors. Perfumer Flavorist 2000; 25:37-40.
472. Gupta PK, Lam FC, Hung CT. Investigation of the stability of doxorubicin hydrochloride using factorial design. Drug Dev Ind Pharm 1988; 14:1657-1671.
473. Yajima T, Umeki N, Shigeru I. Optimum, spray congealing conditions for masking the bitter taste of clarithromycin in wax matrix. Chem Pharm Bull 1999; 47:220-225.
474. Yajima T, Nogata A, Demachi M, Umeki N, Itai S, Yunoki N, Nemoto M. Particle design for taste-masking using a spray-congealing technique. Chem Pharm Bull 1996; 44:187-191.
475. Worakul N, Wongpoowarak W, Boonme P. Optimization in development of acetaminophen syrup formulation. Drug Dev Ind Pharm 2002; 28:345-351.
476. Fransson JR. Oxidation of human insulin-like growth factor I in formulation studies. 3. Factorial experiments of the effects of ferric ions, EDTA, and visible light on methionine oxidation and covalent aggregation in aqueous solution. J Pharm Sci 1997; 86:1046-1050.
477. Bloomfield MS, Butler WC. Robustness testing, using experimental design, of a flow-through dissolution method for a product where the actives have markedly differing solubility properties. Int J Pharm 2000; 206:55-61.
478. Akesolo U, Maguregui MI, Gonzalez L, Jimenez RM, Alonso RM. Experimental design optimization of a capillary zone electrophoresis method for the screening of several diuretics and ACE inhibitors. J Chromatogr Sci 2004; 42:74-79.
479. Li J, Shah DS. Prediction of internal standards in reversed-phase liquid chromatography. II. Selectivity optimization and internal standard prediction for the quantitation of estradiol and levonorgestrel in a transdermal drug delivery formulation based on the linear solvation energy relationships. J Chromatogr A 2002; 954:159-171.
480. Filimonov VN, Zamuruev OV, Balyatinskaya LN, Kolosova IF, Denisova LV. Optimization and evaluation of applicability of HPLC for validation of the quality index of multivitamin pharmaceuticals. Diagnostika Materialov 2001; 67:8-13.
481. Furlanetto S, Orlandini S, La Porta E, Coran S, Pinzauti S. Optimization and validation of a CZE method for rufloxacin hydrochloride determination in coated tablets. J Pharm Biomed Anal 2002; 28:1161-1171.
482. Khuri AI, Conlon M. Simultaneous optimization of multiple responses represented by polynomial regression functions. Technometrics 1981; 23:363-375.
483. Banker GS, Anderson NR. Tablets. In: Lachman L, Lieberman HA, Kanig JL, editors. The Theory and Practice of Industrial Pharmacy. 3 ed. Bombay: Varghese Publishing House, 1987.
484. Singh B, Kumar R, Ahuja N. Optimizing drug delivery systems using systematic design of experiments. Part I: Fundamental aspects. Crit Rev Ther Drug Carrier Syst 2005; 22(1):27-106.